Letter to the Editor
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study
B. Sigurgeirsson,
L. Kircik,
O. Nemoto,
I. Mikazans,
S. Haemmerle, H.J. Thurston, C. Papavassilis, H.B. Richards,
Corresponding Author
B. Sigurgeirsson
Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavik, Iceland
Correspondence: B. Sigurgeirsson. E-mail: [email protected]Search for more papers by this authorL. Kircik
Physicians Skin Care, Eastern Parkway Suite 2310, Louisville, Kentucky
Search for more papers by this authorO. Nemoto
Department of Dermatology, Sapporo Skin Clinic, Sapporo, Japan
Search for more papers by this authorI. Mikazans
Department of Infectology and Dermatology, Riga Stradins University, Riga, Latvia
Search for more papers by this authorB. Sigurgeirsson,
L. Kircik,
O. Nemoto,
I. Mikazans,
S. Haemmerle, H.J. Thurston, C. Papavassilis, H.B. Richards,
Corresponding Author
B. Sigurgeirsson
Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavik, Iceland
Correspondence: B. Sigurgeirsson. E-mail: [email protected]Search for more papers by this authorL. Kircik
Physicians Skin Care, Eastern Parkway Suite 2310, Louisville, Kentucky
Search for more papers by this authorO. Nemoto
Department of Dermatology, Sapporo Skin Clinic, Sapporo, Japan
Search for more papers by this authorI. Mikazans
Department of Infectology and Dermatology, Riga Stradins University, Riga, Latvia
Search for more papers by this authorNo abstract is available for this article.
References
- 1Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman S. Patients with palmo-plantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271–275.
- 2Adişen E, Tekin O, Gülekon A, Gürer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 2009; 23: 814–819.
- 3Christophers E, Segaert S, Milligan G, Molta CT, Boggs R. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat 2013; 24: 193–198.
- 4Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179–188.
- 5Leonardi C, Langley RG, Papp K et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429–436.
- 6Livideanu CB, Lahfa M, Mazereeuw-Hautier J, Paul C. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology 2010; 221: 321–323.
- 7Di Lernia V, Guareschi E. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J 2010; 16: 8.
- 8Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
- 9Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412–421.
- 10Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402–411.
- 11Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244.
Citing Literature
